Impact of Follicular and Blood G-CSF on Pregnancy and Implantation Rate During Modified Natural in Vitro Fertility Cycle (G-CSF FIVnat)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2013 by OVO R & D
Sponsor:
Information provided by (Responsible Party):
OVO R & D
ClinicalTrials.gov Identifier:
NCT01668225
First received: June 19, 2012
Last updated: June 21, 2013
Last verified: June 2013
  Purpose

Recently, scientists look into G-CSF (Granulocyte - Colony Stimulatin Factor). The use of this molecule is increasing in reproduction pathology. High level of follicular and blood G-CSF on the day of oocyte retrieval could correlate with higher pregnancy and implantation rates.


Condition Intervention
Fertility Diseases
Procedure: Blood sample

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Impact of Follicular and Blood G-CSF on Pregnangcy and Implantation Rate During Modified Natural in Vitro Fertility Cycle

Resource links provided by NLM:


Further study details as provided by OVO R & D:

Primary Outcome Measures:
  • Serum and / or follicular minimum level of G-CSF predictive of pregnancy [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Serum sample Follicular fluid


Estimated Enrollment: 224
Study Start Date: March 2012
Groups/Cohorts Assigned Interventions
G-CSF FIV nat
Patient following a natural In Vitro Fecondation cycle
Procedure: Blood sample

Taking blood sample of the patient during the day 3, triggering day, oocyte collection day and pregnancy test day.

Taking the follicular fluid during the oocyte collection day


  Eligibility

Ages Eligible for Study:   18 Years to 43 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Women with a natural cycle of an In Vitro Fecondation

Criteria

Inclusion Criteria:

  • Women between 18 and 43 years old
  • Women natural In Vitro Fecondation

Exclusion Criteria:

  • No exclusion criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01668225

Contacts
Contact: Cynthia Levesque (514) 798-2000 ext 755 c.levesque@cliniqueovo.com
Contact: Michael Harnois (514) 798-2000 ext 755 m.harnois@cliniqueovo.com

Locations
Canada, Quebec
Ovo Fertilité Recruiting
Montréal, Quebec, Canada, J4P 2S4
Contact: Shirley Brugerie, Director    (514) 798-2000 ext 753    s.brugerie@cliniqueovo.com   
Contact: Cynthia Levesque, Research assistant    514-798-2000 ext 755    c.levesque@cliniqueovo.com   
Sponsors and Collaborators
OVO R & D
Investigators
Principal Investigator: Pierre Lehmann, MD Clinique ovo
  More Information

No publications provided

Responsible Party: OVO R & D
ClinicalTrials.gov Identifier: NCT01668225     History of Changes
Other Study ID Numbers: OVO-11-02
Study First Received: June 19, 2012
Last Updated: June 21, 2013
Health Authority: Canada: Ethics Committee

ClinicalTrials.gov processed this record on August 28, 2014